Literature DB >> 33417476

Cryoballoon Versus Laserballoon: Insights From the First Prospective Randomized Balloon Trial in Catheter Ablation of Atrial Fibrillation.

Julian K R Chun1,2, Stefano Bordignon1, Jana Last1, Lukas Mayer1, Shota Tohoku1, Simone Zanchi1, Lorenzo Bianchini1, Fabrizio Bologna1, Takahiko Nagase1, Lukas Urbanek1, Shaojie Chen1, Boris Schmidt1.   

Abstract

BACKGROUND: Pulmonary vein isolation (PVI) represents the cornerstone in atrial fibrillation ablation. Cryoballoon and laserballoon catheters have emerged as promising devices but lack randomized comparisons. Therefore, we sought to compare efficacy and safety comparing both balloons in patients with persistent and paroxysmal atrial fibrillation (AF).
METHODS: Symptomatic AF patients (n=200) were prospectively randomized (1:1) to receive either cryoballoon or laserballoon PVI (cryoballoon: n=100: 50 paroxysmal atrial fibrillation + 50 persistent AF versus laserballoon: n=100: 50 paroxysmal atrial fibrillation + 50 persistent AF). All antiarrhythmic drugs were stopped after ablation. Follow-up included 3-day Holter-ECG recordings and office visits at 3, 6, and 12 months. Primary efficacy end point was defined as freedom from atrial tachyarrhythmia between 90 and 365 days after a single ablation. Secondary end points included procedural parameters and periprocedural complications.
RESULTS: Patient baseline parameters were not different between both groups. In all (n=200) complete PVI was obtained and the entire follow-up accomplished. Balloon only PVI was obtained in 98% (cryoballoon) versus 95% (laserballoon) requiring focal touch-up in 2 and 5 patients, respectively. Procedure but not fluoroscopy time was significantly shorter in the cryoballoon group (50.9±21.0 versus 96.0±20.4 minutes; P<0.0001 and 7.4±4.4 versus 8.4±3.2 minutes, P=0.083). Overall, the primary end point of no atrial tachyarrhythmia recurrence was met in 79% (cryoballoon: 80.0% versus laserballoon: 78.0%, P=ns). No death, atrio-esophageal fistula, tamponade, or vascular laceration requiring surgery occurred. In the cryoballoon group, 8 transient but no persistent phrenic nerve palsy were noted compared with 2 persistent phrenic nerve palsy and one transient ischemic attack in the laserballoon group.
CONCLUSIONS: Both balloon technologies represent highly effective and safe tools for PVI resulting in similar favorable rhythm outcome after 12 months. Use of the cryoballoon is associated with significantly shorter procedure but not fluoroscopy time.

Entities:  

Keywords:  arrhythmias; atrial fibrillation; catheter ablation; fluoroscopy; phrenic nerve

Year:  2021        PMID: 33417476     DOI: 10.1161/CIRCEP.120.009294

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  5 in total

Review 1.  Innovations in atrial fibrillation ablation.

Authors:  Jitae A Kim; Khurrum Khan; Riyad Kherallah; Shamis Khan; Ishan Kamat; Owais Ulhaq; Qussay Marashly; Mihail G Chelu
Journal:  J Interv Card Electrophysiol       Date:  2022-04-11       Impact factor: 1.900

2.  Cryoballoon vs. radiofrequency catheter ablation: insights from NOrwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study).

Authors:  Li-Bin Shi; Ole Rossvoll; Pål Tande; Peter Schuster; Eivind Solheim; Jian Chen
Journal:  Europace       Date:  2022-02-02       Impact factor: 5.214

3.  Comparison of the Efficacy and Safety Endpoints of Five Therapies for Atrial Fibrillation: A Network Meta-Analysis.

Authors:  Tongyu Wang; Tingting Fang; Zeyi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-06-03

4.  Evaluation of linear lesion formation and thermodynamics by dragging ablation with the third-generation laser balloon.

Authors:  Takahiko Nagase; So Asano; Hiroshi Fukunaga; Yuhei Kasai; Kanki Inoue; Yukio Sekiguchi; Kohei Tanizaki; Tatsuya Murai; Mamoru Nanasato; Jun Umemura; Junichi Nitta; Mitsuaki Isobe
Journal:  Heart Rhythm O2       Date:  2022-04-15

5.  Efficacy and Safety of Second and Third-Generation Laser Balloon for Paroxysmal Atrial Fibrillation Ablation Compared to Radiofrequency Ablation: A Matched-Cohort.

Authors:  Charles Guenancia; Nefissa Hammache; Clémence Docq; Karim Benali; Darren Hooks; Mathieu Echivard; Nathalie Pace; Isabelle Magnin-Poull; Christian de Chillou; Jean-Marc Sellal
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.